Aliases & Classifications for Apraxia

Summaries for Apraxia

NIH Rare Diseases : 53 Apraxia is a neurological disorder characterized by the inability to perform tasks or movements, despite having the desire and physical ability to perform them. It is caused by damage to the brain, especially the parietal lobe, and can arise from many diseases, tumors, a stroke, or traumatic brain injury. In some cases it is present from birth. There are several types of apraxia, which may occur alone or together. These include:Buccofacial or orofacial apraxia is the inability to carry out facial movements on demand. This may include licking the lips, sticking out the tongue, whistling, coughing, or winking. Ideational apraxia is the inability to carryout learned, complex tasks with multiple, sequential movements. This may include dressing, eating, and bathing. Ideomotor apraxia is the inability to perform a learned task (such as using a tool) or communicate using gestures (like waving good-bye). Limb-kinetic apraxia is the inability to make fine, precise movements with an arm or leg. This may include buttoning a shirt or tying a shoe.  Verbal apraxia is difficulty coordinating mouth and speech movements. Verbal apraxia may be acquired or present from birth. Constructional apraxia is the inability to copy, draw, or construct simple figures. Oculomotor apraxia is difficulty moving the eyes on command. Treatment of apraxia may include physical, speech, or occupational therapy. If apraxia occurs as a symptom of another disorder, treatment should be directed to the underlying condition.

MalaCards based summary : Apraxia, also known as apraxias, is related to ocular motor apraxia and ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Apraxia is APTX (Aprataxin), and among its related pathways/superpathways is DNA Damage. The drugs Acetylcholine and Tolvaptan have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and parietal lobe, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Decreased viability with poly (ADPa89ribose)a89polymerasea891 (PARP) inhibitor

Disease Ontology : 12 An agnosia that is a loss of the ability to map out physical actions in order to repeat them in functional activities.

NINDS : 54 Apraxia (called "dyspraxia" if mild) is a neurological disorder characterized by loss of the ability to execute or carry out skilled movements and gestures, despite having the desire and the physical ability to perform them. Apraxia results from dysfunction of the cerebral hemispheres of the brain, especially the parietal lobe, and can arise from many diseases or damage to the brain. There are several kinds of apraxia, which may occur alone or together. The most common is buccofacial or orofacial apraxia, which causes the inability to carry out facial movements on command such as licking lips, whistling, coughing, or winking. Other types of apraxia include limb-kinetic apraxia (the inability to make fine, precise movements with an arm or leg), ideomotor apraxia (the inability to make the proper movement in response to a verbal command), ideational apraxia (the inability to coordinate activities with multiple, sequential movements, such as dressing, eating, and bathing), verbal apraxia (difficulty coordinating mouth and speech movements), constructional apraxia (the inability to copy, draw, or construct simple figures), and oculomotor apraxia (difficulty moving the eyes on command). Apraxia may be accompanied by a language disorder called aphasia. Corticobasal ganglionic degeneration is a disease that causes a variety of types of apraxia, especially in elderly adults.

Wikipedia : 76 Apraxia is a motor disorder caused by damage to the brain (specifically the posterior parietal cortex)... more...

Related Diseases for Apraxia

Diseases related to Apraxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 ocular motor apraxia 34.7 APTX NPHP1
2 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 34.7 APTX SETX
3 spinocerebellar ataxia, autosomal recessive 1 33.7 APTX PIK3R5 SETX
4 spinocerebellar ataxia with axonal neuropathy type 2 33.7 PIK3R5 SETX
5 ideomotor apraxia 33.2 GRN MAPT PSEN1
6 childhood apraxia of speech 33.1 FOXP2 ZGRF1
7 gait apraxia 33.1 GRN PSEN1
8 agraphia 31.2 GRN MAPT PSEN1
9 pick disease of brain 31.1 GRN MAPT PSEN1
10 joubert syndrome 1 31.0 CEP104 INPP5E NPHP1
11 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.6 GRN MAPT
12 aceruloplasminemia 30.4 APTX ATM SETX
13 progressive non-fluent aphasia 30.0 C9orf72 GRN MAPT PSEN1
14 supranuclear palsy, progressive, 1 29.1 C9orf72 GRN MAPT PSEN1
15 dementia 29.1 C9orf72 GRN MAPT PSEN1
16 visual agnosia 29.1 GRN PSEN1
17 motor neuron disease 28.9 C9orf72 GRN MAPT SETX
18 frontotemporal dementia 28.8 C9orf72 GRN MAPT PSEN1
19 aphasia 28.8 C9orf72 FOXP2 GRN MAPT PSEN1
20 semantic dementia 28.4 C9orf72 GRN MAPT PSEN1
21 amyotrophic lateral sclerosis 1 28.1 C9orf72 GRN MAPT PSEN1 SETX
22 ataxia-oculomotor apraxia 3 12.3
23 ataxia-oculomotor apraxia 4 12.3
24 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 12.3
25 apraxia of eyelid opening 12.0
26 primary progressive apraxia of speech 12.0
27 autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome 11.8
28 x-linked intellectual disability-ataxia-apraxia syndrome 11.8
29 agnosia 11.5
30 pilarowski-bjornsson syndrome 11.5
31 foxp2-related speech and language disorders 11.5
32 poretti-boltshauser syndrome 11.4
33 birk-landau-perez syndrome 11.4
34 balint syndrome 11.4
35 ataxia-telangiectasia 11.2
36 wieacker-wolff syndrome 11.2
37 corticobasal degeneration 11.1
38 alzheimer disease 3 11.1
39 simultanagnosia 11.0
40 specific language impairment 11.0
41 intellectual disability-developmental delay-contractures syndrome 11.0
42 joubert syndrome 2 10.9
43 joubert syndrome 16 10.9
44 joubert syndrome 25 10.9
45 joubert syndrome 6 10.8
46 joubert syndrome 15 10.8
47 spastic ataxia 5, autosomal recessive 10.8
48 mitochondrial complex iii deficiency, nuclear type 2 10.8
49 joubert syndrome 21 10.8
50 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 10.8

Graphical network of the top 20 diseases related to Apraxia:



Diseases related to Apraxia

Symptoms & Phenotypes for Apraxia

UMLS symptoms related to Apraxia:


cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, muscle rigidity, seizures, signs and symptoms, signs and symptoms, digestive, syncope, torticollis, vertigo, clumsiness, abnormality of extrapyramidal motor function, other symbolic dysfunction, hot flushes, symptoms

GenomeRNAi Phenotypes related to Apraxia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.35 APTX ATM PNKP SETX XRCC1
2 Decreased viability with poly (ADPa89ribose)a89polymerasea891 (PARP) inhibitor GR00114-A 9.16 ATM PNKP
3 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 FOXP2 MAPT PIK3R5 PNKP PSEN1

MGI Mouse Phenotypes related to Apraxia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 APTX ATM C9orf72 GRN INPP5E MAPT
2 nervous system MP:0003631 9.28 ATM C9orf72 GRN INPP5E MAPT NPHP1

Drugs & Therapeutics for Apraxia

Drugs for Apraxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4 51-84-3 187
2
Tolvaptan Approved Phase 4 150683-30-0 216237
3 abobotulinumtoxinA Phase 4
4 Cholinergic Agents Phase 4
5 Neurotransmitter Agents Phase 4,Phase 2
6 onabotulinumtoxinA Phase 4
7 Botulinum Toxins, Type A Phase 4
8 Botulinum Toxins Phase 4
9 Fluorodeoxyglucose F18 Phase 4,Phase 1
10 Radiopharmaceuticals Phase 4
11 Liver Extracts Phase 4
12 Natriuretic Agents Phase 4
13 Hormones Phase 4
14 Vasopressins Phase 4
15 Arginine Vasopressin Phase 4
16
Ethanol Approved Phase 3 64-17-5 702
17
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
18 Micronutrients Phase 3
19 Trace Elements Phase 3
20 Vitamins Phase 3
21 Ubiquinone Phase 3
22 Complement System Proteins Phase 3
23 Fibrinolytic Agents Phase 3
24 Tissue Plasminogen Activator Phase 3
25 Plasminogen Phase 3
26 Lecithin Nutraceutical Phase 3
27
Memantine Approved, Investigational Phase 2 19982-08-2 4054
28
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
29
Benzocaine Approved, Investigational Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
30 tannic acid Approved, Nutraceutical Phase 2,Not Applicable
31 Dopamine Agents Phase 2
32 Excitatory Amino Acid Antagonists Phase 2
33 Excitatory Amino Acids Phase 2
34 Antiparkinson Agents Phase 2
35
Corticosterone Experimental Phase 1 50-22-6 5753
36 Deoxyglucose Phase 1
37
Calcium Carbonate Approved, Investigational Not Applicable 471-34-1
38
Menthol Approved Not Applicable 2216-51-5 16666
39
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
40
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
41
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
42
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
43 Ergocalciferols
44 Bone Density Conservation Agents
45 Prednisolone acetate Not Applicable
46 Methylprednisolone acetate Not Applicable
47 Methylprednisolone Hemisuccinate Not Applicable
48 Prednisolone hemisuccinate Not Applicable
49 Prednisolone phosphate Not Applicable
50 Dermatologic Agents Not Applicable

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
2 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
3 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
4 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
5 App Based Dexterity Training in Multiple Sclerosis Recruiting NCT03369470 Phase 3
6 Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms Recruiting NCT02790034 Phase 2, Phase 3 Sarizotan;Placebo
7 Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. Not yet recruiting NCT03187405 Phase 3 EVD + IVF with Alteplase
8 Electrical Polarization of the Brain in Corticobasal Syndrome Completed NCT00273897 Phase 2
9 A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease Completed NCT02260674 Phase 2 JNJ-54861911, 10 milligram (mg);JNJ-54861911, 50 mg;Placebo
10 A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM) Completed NCT01372449 Phase 2 Memantine;Placebo
11 Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. Completed NCT01701544 Phase 1, Phase 2
12 Transcranial Magnetic Stimulation to Improve Gesture Control Recruiting NCT03483909 Phase 1, Phase 2
13 Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control Recruiting NCT03463902 Phase 1, Phase 2
14 Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Recruiting NCT02696044 Phase 2 triheptanoin
15 Evaluating Anodal tDCS Preceding Aphasia Therapy Terminated NCT02249819 Phase 1, Phase 2
16 PiB PET Scanning in Speech and Language Based Dementias Completed NCT01623284 Phase 1 C-11 PiB;F-18 FDG
17 Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke Unknown status NCT02199093 Not Applicable
18 Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia Unknown status NCT02307019 Not Applicable
19 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628 Not Applicable
20 Action Observation Treatment (AOT) as a Rehabilitation Tool Unknown status NCT02235350 Not Applicable
21 Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy Unknown status NCT01046760
22 Transcranial and Rapid Magnetic Stimulation for Gait Apraxia Due to Normal Pressure Hydrocephalus and Cerebral Ischemia Unknown status NCT00494689
23 Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio) Unknown status NCT01314638
24 Alzheimer's Disease and Related Disorders Unknown status NCT01315704 Drug intervention
25 Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech Completed NCT02094014
26 Occupational Therapy in Patients With Multiple Sclerosis Completed NCT01507636 Not Applicable
27 EEG and EMG Analysis of Ideomotor Apraxia Completed NCT00024999
28 Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program Completed NCT01097161 Not Applicable
29 Using fMRI to Understand the Roles of Brain Areas for Fine Hand Movements Completed NCT00063115
30 Immersive Virtual Environments and Wearable Haptic Devices in Rehabilitation of Children With Neuromotor Impairments Completed NCT03353623 Not Applicable
31 Gait and Alzheimer Interaction Tracking (GAIT) Study Completed NCT01315717
32 Orientation Agnosia: Clinical and Anatomical Study Completed NCT01304576 Not Applicable
33 Delirium in the Emergency Department: Novel Screening Completed NCT01162343
34 Cognitive Training in Parkinson's Disease Completed NCT01393353 Not Applicable
35 Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study Completed NCT01512264 Not Applicable
36 Upper Limbs Intervention in Multiple Sclerosis Completed NCT02047825 Not Applicable
37 Clinical Findings in General Paresis Completed NCT00921648
38 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937 Not Applicable
39 Determinants of Balance Recovery After Stroke - Retrospective Study Completed NCT03203109
40 The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Recruiting NCT03313011
41 Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS) Recruiting NCT03028324 Not Applicable
42 Rehabilitating (Stroke-induced) Apraxia With Direct Current Stimulation Recruiting NCT03185234 Not Applicable
43 Treating Childhood Apraxia of Speech Recruiting NCT03238677 Not Applicable
44 Treatment Intensity - Apraxia of Speech Recruiting NCT02332915 Not Applicable
45 Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT) Recruiting NCT02554513 Not Applicable
46 Evaluation of Intensive Language Therapy Recruiting NCT02935842 Not Applicable
47 Memory for Action in Neurological Patients Recruiting NCT02844855 Not Applicable
48 Rehabilitation Combined With Bihemispherictranscranial Direct Current Stimulation in Subacute Ischemic Stroke Recruiting NCT01644929 Not Applicable
49 Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study Recruiting NCT01904799 Not Applicable
50 Reliability and Validity of a Computerized Tool to Assess Proprioception and Motor Planning Among Children With Coordination Disorders Recruiting NCT03285776

Search NIH Clinical Center for Apraxia

Genetic Tests for Apraxia

Genetic tests related to Apraxia:

# Genetic test Affiliating Genes
1 Apraxia 29

Anatomical Context for Apraxia

MalaCards organs/tissues related to Apraxia:

41
Brain, Eye, Parietal Lobe, Cortex, Tongue, Testes, Bone

Publications for Apraxia

Articles related to Apraxia:

(show top 50) (show all 819)
# Title Authors Year
1
Assessing Anosognosia in Apraxia of Common Tool-Use With the VATA-NAT. ( 29636672 )
2018
2
Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. ( 29799310 )
2018
3
Oculomotor apraxia and disrupted sleep with nocturnal ballistic bouts in ADCY5-related disease. ( 29680308 )
2018
4
Tau Uptake in Agrammatic Primary Progressive Aphasia with and without Apraxia of Speech. ( 29935044 )
2018
5
Constructional Apraxia. ( 29587996 )
2018
6
Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. ( 29353121 )
2018
7
Disrupted functional connectivity in primary progressive apraxia of speech. ( 29845010 )
2018
8
Treating Childhood Apraxia of Speech With the Kaufman Speech to Language Protocol: A Phase I Pilot Study. ( 29625432 )
2018
9
Interventions for childhood apraxia of speech. ( 29845607 )
2018
10
Contemporary Approaches to the Management of Post-stroke Apraxia of Speech. ( 29359303 )
2018
11
Constructional Apraxia in Older Patients with Brain Tumors: Considerations with an Up-To-Date Review of the Literature. ( 29609083 )
2018
12
Ataxia with oculomotor apraxia type 2: an evolving axonal neuropathy. ( 29212862 )
2018
13
Rare compound heterozygous variants in PNKP identified by whole exome sequencing in a German patient with ataxia-oculomotor apraxia 4 and pilocytic astrocytoma. ( 29498415 )
2018
14
Rate and rhythm control strategies for apraxia of speech in nonfluent primary progressive aphasia. ( 29682238 )
2018
15
Apraxia of object-related action does not depend on visual feedback. ( 29202356 )
2018
16
Unilateral Apraxic Agraphia without Ideomotor Apraxia from a callosal lesion in a patient with Marchiafava-Bignami disease. ( 29482459 )
2018
17
Asymmetric oculomotor apraxia, optic ataxia, and simultanagnosia with right hemispatial neglect from a predominantly left-sided lesion of the parieto-occipital area. ( 29199507 )
2018
18
Diagnostic Apraxia and Ictal Alien Hand. ( 29875540 )
2018
19
Error Consistency in Acquired Apraxia of Speech With Aphasia: Effects of the Analysis Unit. ( 29392281 )
2018
20
Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up. ( 29507134 )
2018
21
Model-Driven Treatment of Childhood Apraxia of Speech: Positive Effects of the Speech Motor Learning Approach. ( 29222568 )
2018
22
Apraxia, Neglect, and Agnosia. ( 29851877 )
2018
23
Social Robotics in Therapy of Apraxia of Speech. ( 29713440 )
2018
24
Constructional apraxia. ( 29519467 )
2018
25
Bilateral apraxia of eyelid closure following bilateral subcortical frontal infarcts. ( 29571853 )
2018
26
A new MAPT deletion in a case of speech apraxia leading to corticobasal syndrome. ( 29969053 )
2018
27
Limb apraxia and the left parietal lobe. ( 29519468 )
2018
28
Prosodic and phonetic subtypes of primary progressive apraxia of speech. ( 29980072 )
2018
29
Novel SLC20A2 mutation in primary familial brain calcification with disturbance of sustained phonation and orofacial apraxia. ( 29801865 )
2018
30
Non-right handed primary progressive apraxia of speech. ( 29801898 )
2018
31
Poor Speech Perception Is Not a Core Deficit of Childhood Apraxia of Speech: Preliminary Findings. ( 29450502 )
2018
32
Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1. ( 29356829 )
2018
33
Combined aphasia and apraxia of speech treatment (CAAST): Systematic replications in the development of a novel treatment. ( 28084854 )
2017
34
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: III. Theoretical Coherence of the Pause Marker with Speech Processing Deficits in Childhood Apraxia of Speech. ( 28384751 )
2017
35
Acquired Apraxia of Speech: The Relationship Between Awareness of Errors in Word Productions and Treatment Outcomes. ( 28654947 )
2017
36
Primary progressive apraxia: an unusual ideomotor syndrome. ( 29375885 )
2017
37
Parental experiences and perceptions related to childhood apraxia of speech: Focus on functional implications. ( 28786692 )
2017
38
A 72-year-old with eyelid opening apraxia in Steele-Richardson-Olszewski syndrome. ( 28588873 )
2017
39
Callosal ideomotor apraxia in Alzheimer's disease. ( 27829324 )
2017
40
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: II. Validity Studies of the Pause Marker. ( 28384803 )
2017
41
Parent experiences of variations in service delivery of Rapid Syllable Transition (ReST) treatment for childhood apraxia of speech. ( 28534689 )
2017
42
Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial. ( 29168901 )
2017
43
Botulinum toxin for treating unilateral apraxia of eyelid opening in a patient with congenital myotonia. ( 29160548 )
2017
44
Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. ( 28187331 )
2017
45
Motor Adaptation Deficits in Ideomotor Apraxia. ( 28205499 )
2017
46
Does apraxia support spatial and kinematic or mirror neuron approaches to social interaction? A commentary on Binder etA al. (2017). ( 29167022 )
2017
47
Apraxia: another view. ( 28626022 )
2017
48
Changes in movement transitions across a practice period in childhood apraxia of speech. ( 29281317 )
2017
49
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: IV. The Pause Marker Index. ( 28384662 )
2017
50
Limb-kinetic apraxia in a patient with mild traumatic brain injury: A case report. ( 29390431 )
2017

Variations for Apraxia

Expression for Apraxia

Search GEO for disease gene expression data for Apraxia.

Pathways for Apraxia

Pathways related to Apraxia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 APTX ATM PNKP XRCC1

GO Terms for Apraxia

Cellular components related to Apraxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.72 APTX ATM PNKP SETX XRCC1
2 cell projection GO:0042995 9.63 C9orf72 CEP104 INPP5E MAPT NPHP1 SETX
3 axon GO:0030424 9.56 C9orf72 MAPT PSEN1 SETX
4 main axon GO:0044304 8.96 C9orf72 MAPT
5 growth cone GO:0030426 8.92 C9orf72 MAPT PSEN1 SETX

Biological processes related to Apraxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 post-embryonic development GO:0009791 9.58 ATM FOXP2 PSEN1
2 DNA repair GO:0006281 9.55 APTX ATM PNKP SETX XRCC1
3 positive regulation of telomere maintenance via telomerase GO:0032212 9.48 ATM PNKP
4 positive regulation of neuron death GO:1901216 9.46 ATM MAPT
5 stress granule assembly GO:0034063 9.43 C9orf72 MAPT
6 regulation of autophagy GO:0010506 9.43 ATM C9orf72 MAPT
7 astrocyte activation GO:0048143 9.37 MAPT PSEN1
8 single strand break repair GO:0000012 9.32 APTX XRCC1
9 cellular response to DNA damage stimulus GO:0006974 9.1 APTX ATM PNKP PSEN1 SETX XRCC1
10 negative regulation of protein ADP-ribosylation GO:0010836 8.96 PNKP XRCC1

Molecular functions related to Apraxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.13 APTX MAPT PNKP
2 damaged DNA binding GO:0003684 8.8 APTX PNKP XRCC1

Sources for Apraxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....